Last reviewed · How we verify
NCT05027776
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Phase 3 trial testing 2-doses Group among 9-14 years in HPV Infections in 1,348 participants. Currently enrolling.
22 November 2023
Quick facts
| Lead sponsor | Shanghai Bovax Biotechnology Co., Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 1,348 |
| Start date | 15 September 2021 |
| Primary completion | 22 November 2023 |
| Estimated completion | 29 September 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- 2-doses Group among 9-14 years — full drug profile →
- 3-doses Group among 9-19 years — full drug profile →
- 3-doses Group among 20-26 years — full drug profile →
Conditions studied
- HPV Infections — all drugs for HPV Infections →
- Cervical Cancer Stage IIa — all drugs for Cervical Cancer Stage IIa →
- Vaginal Cancer — all drugs for Vaginal Cancer →
- Genital Wart — all drugs for Genital Wart →
Sponsor
Shanghai Bovax Biotechnology Co., Ltd. — full company profile →
Who can join
Adults 9 to 26, female only, with HPV Infections or Cervical Cancer Stage IIa. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials.
Sobhani N, Scaggiante B, Morris R, Chai D, et al · · 2022 · cited 57× · PMID 35759856 · DOI 10.1016/j.ctrv.2022.102429
Verify or expand the search:
- PubMed search for NCT05027776
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Shanghai Bovax Biotechnology Co., Ltd. trials
Trials by the same sponsor.
- NCT06756269 — To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years · Phase 2 · recruiting
- NCT06454175 — A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years · Phase 1 · active not recruiting
- NCT06465914 — A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males · Phase 3 · active not recruiting
- NCT05584332 — A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Heal · Phase 3 · terminated
- NCT05518201 — Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05027776 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Bovax Biotechnology Co., Ltd.
- Last refreshed: 17 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05027776.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing